Grups d'investigació

Bioprocés en teràpia cel·lular avançada

La nostra recerca se centra en l'optimització de bioprocessos per a la fabricació de teràpies avançades, amb un enfocament translacional orientat a l'aplicació clínica. Treballem principalment amb cèl·lules mesenquimals derivades de medul·la òssia i de cordó umbilical per a aplicacions en regeneració tissular.

Les principals línies d'investigació inclouen la selecció, purificació i caracterització del material de partida, així com l'escalat dels processos productius mitjançant sistemes de biorreactors per a l'obtenció de quantitats clínicament rellevants. Paral·lelament, desenvolupem tecnologies innovadores en l'àmbit de l'enginyeria de teixits, garantint en tot moment la implementació de processos conformes amb la normativa GMP.

Integrants

Cap de grup Joaquim Vives Armengol

Sara Marquina Sierra

Raquel Güell Alonso

Ana Ayala Pérez

Raquel Cabrera Pérez

Mercedes Crespo Hereu

Júlia Falcó Fusté

Lia Brosa Beroy

Laia Martí Melero

Projectes

Investigador/a principal: Joaquim Vives Armengol

Translation of an allogeneic tissue-engineered product for the treatment of focal articular cartilage lesions

Entitat finançadora: Carlos III Institute of Health
Expedient: PI22/01906
Durada: 2023 – 2027

Investigador/a principal: Joaquim Vives Armengol

GALVANO: Optimisation, Validation and Exploitation of a versatile GMP-Grade Extracellular Vesicles Manufacturing Platform for Clinical Application using Process Analytical Technology

Entitat finançadora: Spanish Investigation Agency
Expedient: CPP2023-010430
Durada: 2024 - 2027

Investigador/a principal: Joaquim Vives Armengol

Fibrin Sealant Grifols as scaffold in advanced therapies. 3D printing scaffolds for advanced trauma applications. In vivo study

Entitat finançadora: Instituto Grifols, SA
Expedient: I.2016.035
Durada: 2017 – 2026

Investigador/a principal: Joaquim Vives Armengol

Design and validation of a platform for the production of mesenchymal cells derived from pluripotent cells with genetic characteristics of therapeutic interest and their scaling up in a bioreactor for clinical use

Entitat finançadora: BST
Expedient: I.2023.027
Durada: 2023 – 2026

Investigador/a principal: Angel Raya Chamorro (Bellvitge Biomedical Research Institute), Joaquim Vives Armengol (BST)

Advancing the clinical translation of iPSC-based cell therapies for heart failure

Entitat finançadora: La Marató de TV3 Foundation
Expedient: 268/U/2023
Durada: 2024 – 2027

Investigador/a principal: Manuel Moyano Cudinach (Tecnic Biotech), Joaquim Vives Armengol (BST)

Design and development of the new eLAB MULTI SU bioreactor

Entitat finançadora: Centre for technological development and innovation
Expedient: CPP 6/2023AB
Durada: 2024 – 2026

Investigador/a principal: Joaquim Vives Armengol, Raquel Cabrera Pérez

FLUENTCELLS. Disinformation and malpractice in advanced cell therapy: ethical challenges for effective and appropriate communication with patients, healthcare professionals, and regulators

Entitat finançadora: Víctor Grífols i Lucas Foundation
Expedient: I.2025.037
Durada: 2025 – 2026

Investigador/a principal: Joaquim Vives Armengol

BTCs4ATMP: European network of SOHO establishments for rapid and sustainable access to ATMPs

Entitat finançadora: COST European Cooperation in science & technology
Expedient: CA24114
Durada: 2025 – 2029

Investigador/a principal: Joaquim Vives Armengol

Intercontinental health alliance to develop high impact sustainable educational programmes on quality management in transfusion medicine to enhance accessibility and safety of blood components

Entitat finançadora: EACEA, Erasmus+ CBHE
Expedient: 101235226
Durada: 2023 – 2026

Investigador/a principal: Joaquim Vives Armengol

TRANSMED: Asian Health Alliance: Developing High impact sustainable educational programmes for Transfusion Medicine professionals for safe blood donation and supply

Entitat finançadora: EACEA, Erasmus+ CBHE
Expedient: 101082992
Durada: 2025 – 2028

Publicacions

2025 Cabrera-Pérez R, Carreras-Sánchez I, Roig-Molina Á, López-Fernández A, Portas-Torres I, Batlle-Morera L, Vélez R, Vives J.
Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton's Jelly Mesenchymal Stromal Cells.

Cells. 2025 Jun 7;14(12):862. doi: 10.3390/cells14120862. PMID: 40558490; PMCID: PMC12191425. IF 5.1. Q2.
2025 Güell-Alonso R, Cabrera-Pérez R, Vives J.
Immunocompatibility in transplantation: adapting to a changing therapeutic landscape.

FRONT IMMUNOL. 2025 Sep 9;16:1648534. doi: 10.3389/fimmu.2025.1648534. PMID: 40995364; PMCID: PMC12454034. IF 5.9. Q1.
2024 Sanchez-Guijo F, Vives J, Ruggeri A, Chabannon C, Corbacioglu S, Dolstra H, Farge D, Gagelmann N, Horgan C, Kuball J, Neven B, Rintala T, Rocha V, Sanchez-Ortega I, Snowden JA, Zwaginga JJ, Gnecchi M, Sureda A.
Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

CYTOTHERAPY 2024 Feb 17:S1465-3249(24)00054-9. doi: 10.1016/j.jcyt.2024.02.007. PMID: 38416085. IF 4.5. Q2.
2024 Pérez-Torres Lobato M, Benitez-Carabante MI, Alonso L, Torrents S, Castillo Flores N, Uria Oficialdegui ML, Panesso M, Alonso-Martínez C, Oliveras M, Renedo-Miró B, Vives J, Diaz-de-Heredia C.
Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience.

FRONT PEDIATR 2024 May 9;12:1375493. doi: 10.3389/fped.2024.1375493. PMID: 38783918; PMCID: PMC11112085. IF 2.6. Q2.
2024 López-Fernández A, Codinach M, Coca MI, Prat-Vidal C, Castaño J, Torrents S, Aran G, Rodríguez L, Querol S, Vives J.
Comparability exercise of critical quality attributes of clinical-grade human mesenchymal stromal cells from the Wharton's jelly: single-use stirred tank bioreactors versus planar culture systems.

CYTOTHERAPY 2024 May;26(5):418-426. doi: 10.1016/j.jcyt.2023.08.008. Epub 2023 Sep 16. PMID: 37715777. IF 4.5. Q2.
2024 López-Fernández A, Garcia-Gragera V, Lecina M, Vives J.
Identification of critical process parameters for expansion of clinical grade human Wharton's jelly-derived mesenchymal stromal cells in stirred-tank bioreactors.

BIOTECHNOL J 2024 Feb;19(2):e2300381. doi: 10.1002/biot.202300381. PMID: 38403461. IF 4.7. Q1.
2024 Chaverri D, Gallardo-Villares S, Pinto JA, Rodríguez L, Codinach M, García-López J, Querol S, Coll R, Vives J, Granell-Escobar F.
Treatment of non-hypertrophic pseudoarthrosis of long bones with a Tissue Engineered Product loaded with autologous bone marrow-derived Mesenchymal Stromal Cells: Results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft.

INJURY 2024 Jul;55(7):111596. doi: 10.1016/j.injury.2024.111596. Epub 2024 May 1. PMID: 38797000. IF 2.5. Q2.
2024 Bayes-Genis A, Gastelurrutia P, Monguió-Tortajada M, Cámara ML, Prat-Vidal C, Cediel G, Rodríguez-Gómez L, Teis A, Revuelta-López E, Ferrer-Curriu G, Roura S, Gálvez-Montón C, Bisbal F, Vives J, Vilarrodona A, Muñoz-Guijosa C, Querol S.
Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial.

EBIOMEDICINE 2024 Apr;102:105060. doi: 10.1016/j.ebiom.2024.105060. Epub 2024 Mar 14. PMID: 38490102; PMCID: PMC10955661. IF 11.1. Q1.
2023 Torrents S, Grau-Vorster M, Vives J.
Potency Assays: The 'Bugaboo' of Stem Cell Therapy.

ADV EXP MED BIOl. 2023;1420:29-38. doi: 10.1007/978-3-031-30040-0_3. PMID: 37258782.
2023 Torrents S, Grau-Vorster M, Vives J.
Illustrative Potency Assay Examples from Approved Therapies.

ADV EXP MED BIOL. 2023;1420:139-149. doi: 10.1007/978-3-031-30040-0_9. PMID: 37258788. IF 3.5. Q2.
2023 Vives J, Sánchez-Guijo F, Gnecchi M, Zwaginga JJ.
Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe.

CYTOTHERAPY. 2023 Jul 27:S1465-3249(23)00982-9. doi: 10.1016/j.jcyt.2023.06.006. Epub ahead of print. PMID: 37498257. IF 4,5. Q2.
2023 Torrents S, Del Moral AE, Codinach M, Rodríguez L, Querol S, Vives J.
Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use.

Immunol Res. 2023 Apr 29:1-10. doi: 10.1007/s12026-023-09385-1. Epub ahead of print. PMID: 37120479; PMCID: PMC10148700. IF 4.4. Q2.
2023 Martorell L, López-Fernández A, García-Lizarribar A, Sabata R, Gálvez-Martín P, Samitier J, Vives J.
Preservation of critical quality attributes of mesenchymal stromal cells in 3D bioprinted structures by using natural hydrogel scaffolds.

BIOTECHNOL BIOENG. 2023 Mar 14. doi: 10.1002/bit.28381. PMID: 36919270. IF 3.8. Q2.
2023 Manchanayake GS, García-López J, Vives J.
Analysis of key indicators of research, development, and innovation in blood establishments and their impact on the delivery of improved quality Health products and services.

GLOB J TRANSFUS MED 2023;8:57-61.
2023 López-Fernández A, Codinach M, Coca MI, Prat-Vidal C, Castaño J, Torrents S, Aran G, Rodríguez L, Querol S, Vives J.
Comparability exercise of critical quality attributes of clinical-grade human mesenchymal stromal cells from the Wharton's jelly: single-use stirred tank bioreactors versus planar culture systems.

CYTOTHERAPY. 2023 Sep 15:S1465-3249(23)01039-3. doi: 10.1016/j.jcyt.2023.08.008. Epub ahead of print. PMID: 37715777. IF 4,5. Q2.
2023 Delgadillo J, Kerkelä E, Waters A, Akker EVD, Lechanteur C, Baudoux E, Gardiner N, De Vos J, Vives J.
A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe.

CYTOTHERAPY. 2023 Sep 5:S1465-3249(23)01015-0. doi: 10.1016/j.jcyt.2023.08.001. Epub ahead of print. PMID: 37737767. IF 4.5. Q2.
2023 Cabrera-Pérez R, Ràfols-Mitjans A, Roig-Molina Á, Beltramone S, Vives J, Batlle-Morera L.
Human Wharton's jelly-derived mesenchymal stromal cells promote bone formation in immunodeficient mice when administered into a bone microenvironment.

J TRANSL MED. 2023 Nov 10;21(1):802. doi: 10.1186/s12967-023-04672-9. PMID: 37950242. IF 7.4. Q1.
2022 Vives J, Sòria MG, McGrath E, Magri M.
The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance.

CELLS 2022 Jul 5;11(13):2112. doi: 10.3390/cells11132112. PMID: 35805196; PMCID: PMC9265754. IF 7.666. Q2.
2022 Vives J, Hernández J, Mirabel C, Puigdomenech-Poch M, Romeo-Guitart D, Marmolejo-Martínez-Artesero S, Cabrera-Pérez R, Jaramillo J, Kumru H, García-López J, Vidal-Samsó J, Navarro X, Coll-Bonet R.
Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton's Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance.

CELLS 2022 Jul 8;11(14):2153. doi: 10.3390/cells11142153. PMID: 35883596; PMCID: PMC9319990. IF 7.666. Q2.
2022 Muñoz-Domínguez N, Carreras-Sánchez I, López-Fernández A, Vives J.
Optimisation of processing methods to improve success in the derivation of human multipotent mesenchymal stromal cells from cryopreserved umbilical cord tissue fragments.

CRYOBIOLOGY 2022 Aug 27:S0011-2240(22)00088-8. doi: 10.1016/j.cryobiol.2022.08.002. PMID: 36041506. IF 2.728. Q3.
2022 Lopez-Navas L, Torrents S, Sánchez-Pernaute R, Vives J.
Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies.

STEM CELLS TRANSL MED. 2022 Jul 13:szac046. doi: 10.1093/stcltm/szac046. Epub ahead of print. PMID: 35830540. IF 7.655. Q1.
2022 Fernandez-Sojo J, Delgadillo J, Vives J, Rodriguez L, Mendoza A, Azqueta C, Garcia-Buendia A, Valdivia E, Martorell L, Rubio-Lopez N, Linares M, Alonso S, Ancochea A, García-Rey E, García-Muñoz N, Medina L, Querol S.
A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience.

CYTOTHERAPY 2022 Aug 27:S1465-3249(22)00741-1. doi: 10.1016/j.jcyt.2022.07.011. PMID: 36041984. IF 6.196. Q1.
2021 Vives J, Amposta J.
Chapter 18. Risk management. In: Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy, The EBMT QM Handbook

Ed. Aljurf M, Snowden JA, Orchard KH, Hayden P, McGrath E), 165-176. doi: 10.1007/978-3-030-64492-5_18
2021 Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, Rodríguez L, Codinach M, Hernández J, Navarro X, Vidal J.
Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study.

CYTOTHERAPY. 2021 Feb;23(2):146-156. doi: 10.1016/j.jcyt.2020.08.008. Epub 2020 Sep 25. PMID: 32981857. IF 6.196. Q1.
2021 Ramallo M, Carreras-Sánchez I, Lopez-Fernandez A, Vélez R, Aguirre M, Feldman S, Vives J.
Advances in translational orthopaedic research with species-specific multipotent Mesenchymal Stromal Cells derived from the umbilical cord.

HISTOL&HISTOPATHOL 2021. 36 FI 2,303, QUARTIL 3
2021 García-López J, Delgadillo J, Vilarrodona A; Querol S, Ovejo J, Coll R, Millan A, Madrigal A, Soria G, Vidal F, Vives J, Herrero MJ, Lopez I, Sauleda S, Contreras E, Grifols JR, Guasch R, Tahull E, Puig L, Masip A, Argelagués E, Muñiz-Díaz E.
SARS-COV2/COVID-19 pandemic, first round. Impact, response and lessons learnt on a fully integrated regional blood and tissue bank: a narrative report.

BLOOD TRANSFUSION 2021. FI 3,443, QUARTIL 2
2021 Muñoz-Domínguez N, Roura S, Prat-Vidal C, Vives J.
Wharton's Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View.

PHARMACEUTICS 2021 Aug 26;13(9):1336. FI 6,321, QUARTIL 1
2021 Gastelurrutia P, Prat-Vidal C, Vives J, Coll R, Bayès-Genís A, Gálvez-Montón C.
Transitioning from preclinical evidence to advanced therapy medicinal product: A Spanish experience.

FRONT CARDIOVASCULAR MED 04 Feb 2021. FI 6,050, QUARTIL 1
2021 García-Muñoz E, Vives J.
Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use.

CYTOTECHNOLOGY 2021 May 10:1-10. FI 2,058, QUARTIL 4
2021 Chaverri D, Vivas D, Gallardo-Villares S, Granell-Escobar F, Pinto JA, Vives J.
A pilot study of circulating levels of TGF-β1 and TGF-β2 as biomarkers of bone healing in patients with non-hypertrophic pseudoarthrosis of long bones.

BONE REP 2021 Dec 9;16:101157. FI 3,713, QUARTIL 2
2021 Carreras-Sánchez I, López-Fernández A, Rojas-Márquez R, Vélez R, Aguirre M, Vives J.
Derivation of Mesenchymal Stromal Cells from Ovine Umbilical Cord Wharton's Jelly.

CURR PROTOC 2021 Jan;1(1):e18.

Tesis

Mesenchymal Stem Cells and Microcarrier Technology: a Stem Cell Drug for Osteal Application
Víctor Garcia Gragera (Joaquim Vives Armengol i Martí Lecina Veciana)
Característiques rellevants de les WJ-MSC per al seu ús en malalties del sistema immune
Sílvia Torrents Zapata (Joaquim Vives Armengol i Sergi Querol Giner)
Impacte de la disparitat en HLA en la funcionalitat de productes ossis d’enginyeria tissular basats en cèl·lules mesenquimals
Raquel Güell Alonso (Joaquim Vives Armengol i Raquel Cabrera Pérez)
Bioengineered immunocompatible cell-based constructs for bone regeneration
Ana Ayala Pérez (Joaquim Vives Armengol i Josep Samitier Martí)
Utilització de les cèl·lules mare mesenquimals de la gelatina de Wharton en productes d’enginyeria tissular per a regeneració òssia i condral
Irene Portas Torres (Joaquim Vives Armengol, Raquel Cabrera Pérez, Nayana Joshi Jubert)

Bioprocés en teràpia cel·lular avançada

Integrants

Cap de grup Joaquim Vives Armengol

Sara Marquina Sierra

Raquel Güell Alonso

Ana Ayala Pérez

Raquel Cabrera Pérez

Mercedes Crespo Hereu

Júlia Falcó Fusté

Lia Brosa Beroy

Laia Martí Melero

Projectes

Translation of an allogeneic tissue-engineered product for the treatment of focal articular cartilage lesions

GALVANO: Optimisation, Validation and Exploitation of a versatile GMP-Grade Extracellular Vesicles Manufacturing Platform for Clinical Application using Process Analytical Technology

Fibrin Sealant Grifols as scaffold in advanced therapies. 3D printing scaffolds for advanced trauma applications. In vivo study

Design and validation of a platform for the production of mesenchymal cells derived from pluripotent cells with genetic characteristics of therapeutic interest and their scaling up in a bioreactor for clinical use

Advancing the clinical translation of iPSC-based cell therapies for heart failure

Design and development of the new eLAB MULTI SU bioreactor

FLUENTCELLS. Disinformation and malpractice in advanced cell therapy: ethical challenges for effective and appropriate communication with patients, healthcare professionals, and regulators

BTCs4ATMP: European network of SOHO establishments for rapid and sustainable access to ATMPs

Intercontinental health alliance to develop high impact sustainable educational programmes on quality management in transfusion medicine to enhance accessibility and safety of blood components

TRANSMED: Asian Health Alliance: Developing High impact sustainable educational programmes for Transfusion Medicine professionals for safe blood donation and supply

Publicacions

Preclinical Assessment in Juvenile Sheep of an Allogeneic Bone Tissue Engineering Product with Wharton's Jelly Mesenchymal Stromal Cells.

Immunocompatibility in transplantation: adapting to a changing therapeutic landscape.

Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience.

Comparability exercise of critical quality attributes of clinical-grade human mesenchymal stromal cells from the Wharton's jelly: single-use stirred tank bioreactors versus planar culture systems.

Identification of critical process parameters for expansion of clinical grade human Wharton's jelly-derived mesenchymal stromal cells in stirred-tank bioreactors.

Treatment of non-hypertrophic pseudoarthrosis of long bones with a Tissue Engineered Product loaded with autologous bone marrow-derived Mesenchymal Stromal Cells: Results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft.

Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial.

Potency Assays: The 'Bugaboo' of Stem Cell Therapy.

Illustrative Potency Assay Examples from Approved Therapies.

Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe.

Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use.

Preservation of critical quality attributes of mesenchymal stromal cells in 3D bioprinted structures by using natural hydrogel scaffolds.

Analysis of key indicators of research, development, and innovation in blood establishments and their impact on the delivery of improved quality Health products and services.

Comparability exercise of critical quality attributes of clinical-grade human mesenchymal stromal cells from the Wharton's jelly: single-use stirred tank bioreactors versus planar culture systems.

A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe.

Human Wharton's jelly-derived mesenchymal stromal cells promote bone formation in immunodeficient mice when administered into a bone microenvironment.

The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Opportunity for Integrating Standards and Streamlining Quality Compliance.

Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton's Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance.

Optimisation of processing methods to improve success in the derivation of human multipotent mesenchymal stromal cells from cryopreserved umbilical cord tissue fragments.

Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies.

A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience.

Chapter 18. Risk management. In: Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy, The EBMT QM Handbook

Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study.

Advances in translational orthopaedic research with species-specific multipotent Mesenchymal Stromal Cells derived from the umbilical cord.

SARS-COV2/COVID-19 pandemic, first round. Impact, response and lessons learnt on a fully integrated regional blood and tissue bank: a narrative report.

Wharton's Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View.

Transitioning from preclinical evidence to advanced therapy medicinal product: A Spanish experience.

Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use.

A pilot study of circulating levels of TGF-β1 and TGF-β2 as biomarkers of bone healing in patients with non-hypertrophic pseudoarthrosis of long bones.

Derivation of Mesenchymal Stromal Cells from Ovine Umbilical Cord Wharton's Jelly.

Tesis

Mesenchymal Stem Cells and Microcarrier Technology: a Stem Cell Drug for Osteal Application

Característiques rellevants de les WJ-MSC per al seu ús en malalties del sistema immune

Impacte de la disparitat en HLA en la funcionalitat de productes ossis d’enginyeria tissular basats en cèl·lules mesenquimals

Bioengineered immunocompatible cell-based constructs for bone regeneration

Utilització de les cèl·lules mare mesenquimals de la gelatina de Wharton en productes d’enginyeria tissular per a regeneració òssia i condral